CENTEK(SZ:000931) Sou Hu Cai Jing·2026-01-28 13:05Core Viewpoint - The stock of Zhongguancun (000931) has shown a decline in price and mixed capital flow, indicating potential challenges in market sentiment and performance [1]. Group 1: Stock Performance - As of January 28, 2026, Zhongguancun's stock closed at 5.15 yuan, down 1.15% with a turnover rate of 1.21% and a trading volume of 91,000 hands, amounting to a transaction value of 47.03 million yuan [1]. - The net outflow of main funds on January 28 was 1.3181 million yuan, accounting for 2.8% of the total transaction value, while retail investors saw a net inflow of 684,000 yuan, representing 1.45% of the total [1]. Group 2: Financial Metrics and Industry Comparison - Zhongguancun's total market value is 3.879 billion yuan, significantly lower than the chemical pharmaceutical industry average of 14.259 billion yuan, ranking 116 out of 146 [2]. - The company's net profit for the first three quarters of 2025 was 49.4914 million yuan, a decrease of 4.14% year-on-year, while the main operating income was 1.882 billion yuan, down 2.46% year-on-year [2]. - The company's gross profit margin stands at 59.64%, which is higher than the industry average of 48.84%, ranking 46 out of 146 [2]. Group 3: Business Segments - Zhongguancun's main business segments include biopharmaceuticals and health products, elderly medical services, commercial concrete, and other businesses [2]. - The biopharmaceutical segment encompasses the research, manufacturing, and sales of various pharmaceutical forms, including chemical drugs and medical devices [2].